Exact Mass: 393.1424

Exact Mass Matches: 393.1424

Found 51 metabolites which its exact mass value is equals to given mass value 393.1424, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Fruquintinib

Fruquintinib

C21H19N3O5 (393.1325)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

   

N-Hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbutanamide hydrochloride

N-Hydroxy-2(R)-[[(4-methoxyphenyl)sulphonyl](3-picolyl)amino]-3-methylbutanamide hydrochloride

C18H23N3O5S (393.1358)


   

Pentetic acid

[[(Carboxymethyl)imino]bis(1,2-ethanediylnitrilo)tetraacetic acid]

C14H23N3O10 (393.1383)


   

1-[5-(2-Cyclopropyl-5,7-dimethylimidazo[4,5-b]pyridin-3-ylmethyl)thiophen-2-yl]cyclopent-3-ene carboxylic acid

1-[5-({2-cyclopropyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl}methyl)thiophen-2-yl]cyclopent-3-ene-1-carboxylic acid

C22H23N3O2S (393.1511)


   

4-(2-Aminoethylamino)-3-[bis(carboxymethyl)amino]-3-(carboxymethyl)hexanedioic acid

4-[(2-aminoethyl)amino]-3-[bis(carboxymethyl)amino]-3-(carboxymethyl)hexanedioic acid

C14H23N3O10 (393.1383)


   
   

SKCHUVDMAXVDEA-UHFFFAOYSA-

SKCHUVDMAXVDEA-UHFFFAOYSA-

C21H19N3O5 (393.1325)


   

2-Deoxy-2-aminokealiiquinone

2-Deoxy-2-aminokealiiquinone

C21H19N3O5 (393.1325)


   

asperloxin A|circumdatin A

asperloxin A|circumdatin A

C21H19N3O5 (393.1325)


   

AMG-073 HCl (Cinacalcet hydrochloride)

AMG-073 HCl (Cinacalcet hydrochloride)

C22H23ClF3N (393.1471)


   

Asn Ser Ser Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-hydroxypropanamido]-3-hydroxypropanamido]-3-hydroxypropanoic acid

C13H23N5O9 (393.1496)


   

Ser Asn Ser Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-carbamoylpropanamido]-3-hydroxypropanamido]-3-hydroxypropanoic acid

C13H23N5O9 (393.1496)


   

Ser Ser Asn Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxypropanamido]-3-carbamoylpropanamido]-3-hydroxypropanoic acid

C13H23N5O9 (393.1496)


   

Ser Ser Ser Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxypropanamido]-3-hydroxypropanamido]-3-carbamoylpropanoic acid

C13H23N5O9 (393.1496)


   

N-Desmethyltrifluoperazine

N-Desmethyltrifluoperazine

C20H22F3N3S (393.1486)


   

Pentetic acid

Diethylenetriaminepentaacetic acid

C14H23N3O10 (393.1383)


D064449 - Sequestering Agents > D002614 - Chelating Agents > D007502 - Iron Chelating Agents D020011 - Protective Agents > D000931 - Antidotes

   

Ent-cinacalcet hydrochloride

Ent-cinacalcet hydrochloride

C22H23ClF3N (393.1471)


   

7-FLUORO-3,4-DIHYDRO-4-[(5-ISOQUINOLINYLOXY)ACETYL]-1,3,3-TRIMETHYL-2(1H)-QUINOXALINONE

7-FLUORO-3,4-DIHYDRO-4-[(5-ISOQUINOLINYLOXY)ACETYL]-1,3,3-TRIMETHYL-2(1H)-QUINOXALINONE

C22H20FN3O3 (393.1489)


   

2,6-BIS((3AS,8AR)-8,8A-DIHYDRO-3AH-INDENO[1,2-D]OXAZOL-2-YL)PYRIDINE

2,6-BIS((3AS,8AR)-8,8A-DIHYDRO-3AH-INDENO[1,2-D]OXAZOL-2-YL)PYRIDINE

C25H19N3O2 (393.1477)


   

Cinacalcet hydrochloride

Cinacalcet hydrochloride

C22H23ClF3N (393.1471)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D057966 - Calcimimetic Agents C78275 - Agent Affecting Blood or Body Fluid > C2136 - Malignancy-Associated Hypercalcemia Inhibitor D000077264 - Calcium-Regulating Hormones and Agents

   

methyl 2-[(3-cyanobenzoyl)amino]-3-(3-methoxypropyl)imidazo[4,5-b]pyridine-6-carboxylate

methyl 2-[(3-cyanobenzoyl)amino]-3-(3-methoxypropyl)imidazo[4,5-b]pyridine-6-carboxylate

C20H19N5O4 (393.1437)


   

O-[BIS(4-METHOXYPHENYL)PHOSPHINYL]-N-(TERT-BUTOXYCARBONYL)HYDROXYLAMINE

O-[BIS(4-METHOXYPHENYL)PHOSPHINYL]-N-(TERT-BUTOXYCARBONYL)HYDROXYLAMINE

C19H24NO6P (393.1341)


   

Befiradol

Befiradol

C20H22ClF2N3O (393.1419)


Befiradol (NLX-112) is a selective 5-HT1A receptor agonist.

   

Phenolphthalein anilide

Phenolphthalein anilide

C26H19NO3 (393.1365)


   

BOC-THIONOLEU-1-(6-NITRO)BENZOTRIAZOLIDE

BOC-THIONOLEU-1-(6-NITRO)BENZOTRIAZOLIDE

C17H23N5O4S (393.1471)


   

2,6-BIS((3AR,8AS)-8,8A-DIHYDRO-3AH-INDENO[1,2-D]OXAZOL-2-YL)PYRIDINE

2,6-BIS((3AR,8AS)-8,8A-DIHYDRO-3AH-INDENO[1,2-D]OXAZOL-2-YL)PYRIDINE

C25H19N3O2 (393.1477)


   

(S)-Cinacalcet hydrochloride

(S)-Cinacalcet hydrochloride

C22H23ClF3N (393.1471)


   
   

4-(3-(4-(1-methyl-1H-pyrazol-5-yl)phenylthio)phenyl)-tetrahydro-2H-pyran-4-carboxamide

4-(3-(4-(1-methyl-1H-pyrazol-5-yl)phenylthio)phenyl)-tetrahydro-2H-pyran-4-carboxamide

C22H23N3O2S (393.1511)


PF-4191834 (PF-04191834) is an orally active, noniron chelating, and non-redox inhibitor of the 5-Lipoxygenase (5-LOX) (IC50=229 nM), displays ~300-fold selectivity for 5-LOX over 12-LOX and 15-LOX, shows no activity toward the cyclooxygenase enzymes, and is effective in inflammation and pain[1].

   

N-Hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbutanamide hydrochloride

N-Hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbutanamide hydrochloride

C18H23N3O5S (393.1358)


D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D061965 - Matrix Metalloproteinase Inhibitors

   

2-fluoro-N-[4-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]phenyl]benzamide

2-fluoro-N-[4-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]phenyl]benzamide

C22H20FN3O3 (393.1489)


   

1-(3,4-dihydro-2H-quinolin-1-yl)-2-[[1-(4-ethoxyphenyl)-2-imidazolyl]thio]ethanone

1-(3,4-dihydro-2H-quinolin-1-yl)-2-[[1-(4-ethoxyphenyl)-2-imidazolyl]thio]ethanone

C22H23N3O2S (393.1511)


   

N-[4-(4-morpholinyl)phenyl]-5-(2-nitrophenyl)-2-furancarboxamide

N-[4-(4-morpholinyl)phenyl]-5-(2-nitrophenyl)-2-furancarboxamide

C21H19N3O5 (393.1325)


   

1-[4-(4-Phenylmethoxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide

1-[4-(4-Phenylmethoxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide

C22H23N3O2S (393.1511)


   

N-(3-imidazol-1-ylpropyl)-2-[(4-nitrobenzoyl)amino]benzamide

N-(3-imidazol-1-ylpropyl)-2-[(4-nitrobenzoyl)amino]benzamide

C20H19N5O4 (393.1437)


   

2-[1-[[[(4-Methoxyphenyl)-oxomethyl]amino]-sulfanylidenemethyl]-3-oxo-2-piperazinyl]acetic acid propan-2-yl ester

2-[1-[[[(4-Methoxyphenyl)-oxomethyl]amino]-sulfanylidenemethyl]-3-oxo-2-piperazinyl]acetic acid propan-2-yl ester

C18H23N3O5S (393.1358)


   

N-{(E)-[2,4,6-trioxo-1-(2,4,6-trimethylphenyl)tetrahydropyrimidin-5(2H)-ylidene]methyl}pyridine-4-carbohydrazide

N-{(E)-[2,4,6-trioxo-1-(2,4,6-trimethylphenyl)tetrahydropyrimidin-5(2H)-ylidene]methyl}pyridine-4-carbohydrazide

C20H19N5O4 (393.1437)


   

[(1S,2aR,8bR)-1-(hydroxymethyl)-2-(4-oxazolylmethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-(3-fluorophenyl)methanone

[(1S,2aR,8bR)-1-(hydroxymethyl)-2-(4-oxazolylmethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-(3-fluorophenyl)methanone

C22H20FN3O3 (393.1489)


   

[(1R,2aS,8bS)-1-(hydroxymethyl)-2-(4-oxazolylmethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-(3-fluorophenyl)methanone

[(1R,2aS,8bS)-1-(hydroxymethyl)-2-(4-oxazolylmethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-(3-fluorophenyl)methanone

C22H20FN3O3 (393.1489)


   

Cyclohexyl 2-methyl-4-thiophen-2-yl-3,4-dihydropyrimido[1,2-a]benzimidazole-3-carboxylate

Cyclohexyl 2-methyl-4-thiophen-2-yl-3,4-dihydropyrimido[1,2-a]benzimidazole-3-carboxylate

C22H23N3O2S (393.1511)


   

Agomelatine (L(+)-Tartaric acid)

Agomelatine (L(+)-Tartaric acid)

C19H23NO8 (393.1424)


Agomelatine L(+)-Tartaric acid (S-20098 L(+)-Tartaric acid) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine L(+)-Tartaric acid is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].

   

CJ-13,610

CJ-13,610

C22H23N3O2S (393.1511)


CJ-13,610, a nonredox-type 5-LO inhibitor, dose dependently suppresses 5-LO product formation in ionophore A23187-stimulated PMNL in the absence of exogenous AA with an IC50 of about 70 nM[1]. PMNL: polymorphonuclear leukocytes; AA: arachidonic acid

   

SCD1 inhibitor-3

SCD1 inhibitor-3

C19H16FN7O2 (393.1349)


SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer[1].

   

(2s)-20-hydroxy-10,18-dimethoxy-6,14,22-triazapentacyclo[12.8.0.0²,⁶.0⁸,¹³.0¹⁶,²¹]docosa-1(22),8,10,12,16,18,20-heptaene-7,15-dione

(2s)-20-hydroxy-10,18-dimethoxy-6,14,22-triazapentacyclo[12.8.0.0²,⁶.0⁸,¹³.0¹⁶,²¹]docosa-1(22),8,10,12,16,18,20-heptaene-7,15-dione

C21H19N3O5 (393.1325)


   

10,19-dimethoxy-7,15-dioxo-6,14,22λ⁵-triazapentacyclo[12.8.0.0²,⁶.0⁸,¹³.0¹⁷,²²]docosa-1(22),8,10,12,16,18,20-heptaen-22-ylium-16-olate

10,19-dimethoxy-7,15-dioxo-6,14,22λ⁵-triazapentacyclo[12.8.0.0²,⁶.0⁸,¹³.0¹⁷,²²]docosa-1(22),8,10,12,16,18,20-heptaen-22-ylium-16-olate

C21H19N3O5 (393.1325)


   

20-hydroxy-10,18-dimethoxy-6,14,22-triazapentacyclo[12.8.0.0²,⁶.0⁸,¹³.0¹⁶,²¹]docosa-1(22),8,10,12,16,18,20-heptaene-7,15-dione

20-hydroxy-10,18-dimethoxy-6,14,22-triazapentacyclo[12.8.0.0²,⁶.0⁸,¹³.0¹⁶,²¹]docosa-1(22),8,10,12,16,18,20-heptaene-7,15-dione

C21H19N3O5 (393.1325)


   

2-imino-6,7-dimethoxy-4-(4-methoxyphenyl)-1-methyl-3h-naphtho[2,3-d]imidazole-5,8-dione

2-imino-6,7-dimethoxy-4-(4-methoxyphenyl)-1-methyl-3h-naphtho[2,3-d]imidazole-5,8-dione

C21H19N3O5 (393.1325)


   

2-[(1r,3s,4ar,10ar)-4a,9,10a-trihydroxy-7-methoxy-5,10-dioxo-1-propyl-1h,3h,4h-naphtho[2,3-c]pyran-3-yl]ethanimidic acid

2-[(1r,3s,4ar,10ar)-4a,9,10a-trihydroxy-7-methoxy-5,10-dioxo-1-propyl-1h,3h,4h-naphtho[2,3-c]pyran-3-yl]ethanimidic acid

C19H23NO8 (393.1424)


   

10,18-dimethoxy-21-oxa-6,14,23-triazapentacyclo[12.9.0.0²,⁶.0⁸,¹³.0¹⁶,²²]tricosa-1(23),8,10,12,16(22),17,19-heptaene-7,15-dione

10,18-dimethoxy-21-oxa-6,14,23-triazapentacyclo[12.9.0.0²,⁶.0⁸,¹³.0¹⁶,²²]tricosa-1(23),8,10,12,16(22),17,19-heptaene-7,15-dione

C21H19N3O5 (393.1325)


   

n-{2-[12-methoxy-11-(methylsulfanyl)-8,14-diazatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2,4,6,9,11,13,15-octaen-10-yl]ethyl}propanimidic acid

n-{2-[12-methoxy-11-(methylsulfanyl)-8,14-diazatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2,4,6,9,11,13,15-octaen-10-yl]ethyl}propanimidic acid

C22H23N3O2S (393.1511)